Home
AI
World
Politics
Health
Crime & justice
Science & technology
Social issues
Sports
Money
Entertainment
Environment/energy
Military
Culture
Weather
Media






Home
Bias Split
Public FiguresControversies

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Sign Up!
Sign Up Now!

How our sliders workAboutContact UsNewsletter Archive
MediaFAQGlossaryPrivacy Policy
  1. Home

Report: FDA Considers Importing Unapproved Cancer Drugs

  • #Health
  • #United States of America
  • #Medicine & healthcare
  • #Cancer
story
JUN 2023
Image copyright: National Cancer Institute [via Wikimedia Commons]
story last updated JUN 2023

The Spin

Left narrative

A cutthroat generic drug industry has exacerbated the worst aspects of the free market. Manufacturers have offshored their factories to reduce FDA inspections and have been caught falsifying clinical trials and with substandard quality control. Most drugs in the US are sourced from outside of the country in the pursuit of profit. A national rating system for companies and factories would force drug companies to clean up their act.

New York Times

Right narrative

Government interference in the market has made it unprofitable to produce lifesaving medicine, as efforts to lower drug prices make drug manufacturing increasingly more expensive and the supply chain more fragile. Pharma troupes are forced to outsource and cut corners to stay solvent — just as the government bears down on them to reduce healthcare spending. Tax cuts and other incentives would help shore up our drug supply.

Wall Street Journal

Metaculus Prediction


Political split

LEFT

RIGHT

F.D.A. Panel Rejects Lilly’s Cancer Drug Tested Only in China
New York TimesJUL 2022
Our Generic Drug Supply Is Sick - The New York Times
New York TimesJUL 2021

More neutral political stance articles

A short supply of cancer drugs has doctors and patients worried: 'We're at a critical juncture'
USA TodayJUL 2023
FDA considers temporary cancer drug imports from unapproved companies to ease U.S. shortage
CNBCJUL 2023
FDA Advisers Say Agency Shouldn’t Approve China-Developed Cancer Drug Now
Wall Street JournalJUL 2022